Sign In
Buy EWTX
$43.52
-0.90 (-2.03%)
At Close: Aug 07, 2026
Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On
04:54pm, Wednesday, 02'nd Apr 2025
The global hypertrophic cardiomyopathy market is expected to reach $1.35 billion by 2031. Despite a temporary stock drop due to adverse events and a $200 million stock offering, the long-term outlook
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
12:27pm, Wednesday, 02'nd Apr 2025
Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyo
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
09:16am, Wednesday, 02'nd Apr 2025
Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise. The post Why Edgewise Therapeutics And Cytokinetics Stocks J
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
06:22am, Wednesday, 02'nd Apr 2025
BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering o
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated subs
BOULDER, Colo. , March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team wil
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an i
Edgewise Therapeutics: More Expensive Now, But Much More Derisked
01:36pm, Monday, 10'th Mar 2025
Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targetin
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
08:00am, Tuesday, 04'th Mar 2025
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners G
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
08:00am, Monday, 03'rd Mar 2025
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data
02:09pm, Tuesday, 31'st Dec 2024
Company achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON st
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
10:20am, Tuesday, 17'th Dec 2024
Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
11:56am, Monday, 16'th Dec 2024
On Monday, Edgewise Therapeutics, Inc., EWTX revealed topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy (BMD), is a genetic disorder that cau
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial
Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research
02:32pm, Thursday, 05'th Dec 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company's relationship with D
